Cantourage Group (HIGH) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
23 Jun, 2026Investment highlights and market position
Leading pan-European medical cannabis platform with profitable growth in regulated markets.
Asset-light, scalable, and capital-efficient business model.
Market leader in Germany, UK, and Poland, with plans for further European expansion.
Diversified product portfolio addressing current and future patient needs.
Market trends and opportunities
Rapidly growing European medical cannabis markets, driven by increasing patient demand.
Over 150 million people in Europe suffer from sleep disorders, 60 million from anxiety, and 100 million from chronic pain.
Medical cannabis adoption is expanding across multiple indications, including neurology, pain, and autoimmune conditions.
Europe is expected to become the world's largest medical cannabis market, with potential upside from recreational legalization.
Business model and operational strengths
Unique asset-light operating model enables profitable growth and flexibility.
Global supply chain allows rapid onboarding of legal cultivators into EU markets.
Telemedicine platforms in Germany and UK streamline patient access and prescription fulfillment.
Revenue-sharing model with growers and a multi-brand strategy support a broad product offering.
Latest events from Cantourage Group
- Net profit surged to €210,989.14 in H1 2024, driven by higher revenue and one-time income.HIGH
H1 202423 Jun 2026 - Revenue and net income grew strongly, with all earnings retained and a clean audit opinion.HIGH
H2 202423 Jun 2026 - Q1 2025 revenue soared to EUR 25.6 million, quadrupling year-over-year on robust European demand.HIGH
Q1 2025 TU23 Jun 2026 - Revenue and profit fell, but equity and liquidity remain robust amid higher compliance costs.HIGH
H1 202523 Jun 2026 - Q2 2025 revenue more than doubled year-over-year, exceeding last year's total annual sales.HIGH
Q2 2025 TU23 Jun 2026 - Revenue up 148% year-over-year to EUR 75 million, with strong growth and European expansion plans.HIGH
Q3 2025 TU23 Jun 2026 - Revenue up 78% to €3.9M, net income €126K, audit unqualified, all sales intra-group.HIGH
H2 202523 Jun 2026 - Q1 2026 saw higher profitability, strong UK growth, and a robust financial position.HIGH
Q1 2026 TU23 Jun 2026